Northwestern Mutual Wealth Management Co. grew its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 1.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 160,039 shares of the company’s stock after acquiring an additional 2,694 shares during the period. Northwestern Mutual Wealth Management Co. owned about 2.37% of VanEck Pharmaceutical ETF worth $14,641,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Optimum Investment Advisors purchased a new position in shares of VanEck Pharmaceutical ETF during the second quarter valued at approximately $27,000. GPS Wealth Strategies Group LLC bought a new stake in VanEck Pharmaceutical ETF in the second quarter worth $42,000. CWM LLC bought a new stake in VanEck Pharmaceutical ETF in the second quarter worth $55,000. International Assets Investment Management LLC bought a new position in shares of VanEck Pharmaceutical ETF during the second quarter valued at $86,000. Finally, Comerica Bank raised its position in shares of VanEck Pharmaceutical ETF by 39.4% in the 1st quarter. Comerica Bank now owns 1,337 shares of the company’s stock worth $121,000 after purchasing an additional 378 shares during the last quarter.
VanEck Pharmaceutical ETF Stock Performance
Shares of PPH stock opened at $94.54 on Wednesday. The company has a market capitalization of $717.56 million, a price-to-earnings ratio of 21.04 and a beta of 0.72. VanEck Pharmaceutical ETF has a one year low of $74.05 and a one year high of $99.51. The company’s 50-day moving average is $95.91 and its 200 day moving average is $91.99.
VanEck Pharmaceutical ETF Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Read More
- Five stocks we like better than VanEck Pharmaceutical ETF
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What are earnings reports?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Using the MarketBeat Dividend Tax Calculator
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
